FOXA1 and fatty liver disease: Although the results of some studies on the role of FOXA appear to be relative:the glucagon-like peptide-1 receptor (GLP-1R) agonist Exendin-4 leads to reduced expression of FOXA1 via the Wnt/Β-catenin pathway, further resulting in a decrease in FABP1, which causes a reduction in fatty acid uptake and prevents the development of hepatic steatosis (105), which seems contradictory to the reduction in fatty acid uptake by FOXA1 found in in vitro experiments.